You are here

Our science / Clinical Trials / Find a Trial / NCT01220180

Lyrica (Pregabalin) Korean Post Marketing Surveillance Study

Back to Search Print Save as PDF Bookmark Trial

NCT01220180

Last updated on April 11, 2018
Back to Search Print Save as PDF Bookmark Trial

FOR MORE INFORMATION
Study Location
Contact
1-800-718-1021
[email protected]
Related Links
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Epilepsy, Neuropathic Pain, Fibromyalgia, Post-market Surveillance
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
0+
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Any patient treated with pregabalin for an approved indication by Korean Food and Drug
Administration

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Non-consenting

- Hypersensitivity to the active substance or to any of the excipients

- galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption.

NCT01220180
Pfizer
Completed
Lyrica (Pregabalin) Korean Post Marketing Surveillance Study

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.
Advanced Search

Similar Trials

Partial Seizures Epilepsy, Primary Generalized Tonic-Clonic Seizures Epilepsy
A 12-Month Study To Evaluate The Safety And Tolerability Of Pregabalin As Add-On Therapy In Pediatric Subjects 1 Month To 16 Years Of Age With Partial Onset Seizures And Pediatric And Adult Subjects 5 To 65 Years Of Age With Primary Generalized Tonic-Clonic Seizures
NCT01463306
All Genders
0+
Years
Multiple Sites
Pain
A Dental Pain Study Comparing The Analgesic Efficacy Of Ibuprofen/Caffeine
NCT02863575
All Genders
16+
Years
Salt Lake City, Utah
Osteoarthritis, Cancer Pain, Recurrent Low Back Pain
Protocol to Monitor the Neurological Development of Infants With Exposure in Utero From Birth to 15 Months in Tanezumab Clinical Studies
NCT03031938
All Genders
0+
Years
Multiple Sites
Low Back Pain
A Phase 3 Study of Tanezumab for Chronic Low Back Pain
NCT02528253
All Genders
18+
Years
Multiple Sites
Lyrica (Pregabalin) Korean Post Marketing Surveillance Study
Post Marketing Surveillance Study For Observing Safety And Efficacy Of Lyrica
This study collects post-marketing safety and efficacy surveillance data in real world clinical use of pregabalin for its approved indications in Korea.
continuous patients with target disorders in collaborating institutions
Observational
Observational Model: Ecologic or Community
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
Korean adult patients with epilepsy, neuropathic pain or fibromyalgia, prescribed pregabalin for within label use
  • Epilepsy
  • Neuropathic Pain
  • Fibromyalgia
  • Post-market Surveillance
  • Drug: pregabalin (Lyrica)
    Pregabalin treatment can be started with a dose of 150 mg per day. Based on individual subject response and tolerability, the dosage may be increased to 300 mg per day after 1 week. The maximum dosage of 600 mg per day may be achieved after an additional week.
  • Drug: pregabalin (Lyrica)

    Peripheral neuropathic pain: Pregabalin treatment can be started at a dose of 150 mg per day. Based on individual subject response and tolerability, the dosage may be increased to 300 mg per day after an interval of 3 to 7 days, and if needed, to a maximum dose of 600 mg per day after an additional 7-day interval.

    Central neuropathic pain: Pregabalin treatment can be started at a dose of 150 mg per day. Based on individual subject response and tolerability, the dosage may be increased to 300 mg per day after an interval of 1 week, and if needed, to a maximum dose of 600 mg per day after an additional 1 week interval. In case that tolerability could not be shown in the targeted daily dose, dose reduction may be considered.

  • Drug: pregabalin (Lyrica)
    The recommended dose of pregabalin for fibromyalgia is 300 to 450 mg/day. Dosing should begin at 75 mg two times a day (150 mg/day) and may be increased to 150 mg two times a day (300 mg/day) within 1 week based on efficacy and tolerability. Subjects who do not experience sufficient benefit with 300 mg/day may be further increased to 225 mg two times a day (450 mg/day). Treatment with doses above 450 mg/day is not recommended.
  • Epilepsy
    Intervention: Drug: pregabalin (Lyrica)
  • Neuropathic Pain
    Intervention: Drug: pregabalin (Lyrica)
  • Fibromyalgia
    Intervention: Drug: pregabalin (Lyrica)
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
4175
April 2011
April 2011   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Any patient treated with pregabalin for an approved indication by Korean Food and Drug Administration

Exclusion Criteria:

  • Non-consenting
  • Hypersensitivity to the active substance or to any of the excipients
  • galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption.
Sexes Eligible for Study: All
Child, Adult, Senior
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
 
NCT01220180
A0081138
No
Not Provided
Not Provided
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
November 2011

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now